Skip to main content
Log in

Discriminating Pheochromocytomas from Other Adrenal Lesions: The Dilemma of Elevated Catecholamines

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Screening tests for pheochromocytoma involve measuring levels of catecholamines in the urine or plasma, which have significant false-positive rates. We reviewed patients with adrenal masses and elevated levels of catecholamines to determine the value of different preoperative tests in diagnosing pheochromocytomas.

Methods

A retrospective chart review identified patients who underwent adrenalectomy between 1997 and 2011 with elevation of urine or serum catecholamines. A database of clinicopathologic factors was created including preoperative urine and plasma metanephrines, normetanephrines, vanillylmandelic acid, and fractionated catecholamines, and tumor dimensions on imaging and pathology.

Results

A total of 70 patients underwent adrenalectomy because of presence of an adrenal mass and elevation of catecholamines or normetanephrines or metanephrines. Of these, 46 had pathologically confirmed pheochromocytomas. To improve our ability to discriminate between pheochromocytoma and other pathology, we examined different combinations of clinicopathologic factors and catecholamine levels and found the best test was a scoring system. Points are awarded for a hierarchy of elevated normetanephrine, norepinephrine, metanephrines, with additional points received for age <50 and size on imaging >3.3 cm. A score of 2 is suggestive of pheochromocytoma, with a positive predictive value of 86–87 %, while a score of 4 is diagnostic with positive predictive value of 100 %.

Conclusion

We found that urine/serum normetanephrine levels were the most valuable screening tool; however, a score examining the size of adrenal mass on preoperative CT, age, and either plasma or urine norepinephrine, metanephrine, and normetanephrine values leads to a higher positive predictive value, making this scoring system superior to individual lab tests.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983; 58:802–4.

    PubMed  CAS  Google Scholar 

  2. Manger WM, Gifford RW. Pheochromocytoma. New York: Springer-Verlag; 1977.

    Book  Google Scholar 

  3. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987; 147:1289–93.

    Article  PubMed  CAS  Google Scholar 

  4. Anderson GH, Jr., Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994; 12:609–15.

    Article  PubMed  Google Scholar 

  5. Young WF, Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000; 29:159–185, x.

  6. Engel A, von EU. Diagnostic value of increased urinary output of pheochromocytoma. Lancet. 1950; 2:387.

    Article  PubMed  CAS  Google Scholar 

  7. Goldenberg M, Serlin I, Edwards T, Rapport MM. Chemical screening methods for the diagnosis of pheochromocytoma. I. Nor-epinephrine and epinephrine in human urine. Am J Med. 1954; 16:310–27.

    Article  PubMed  CAS  Google Scholar 

  8. Lenders JW, Pacak K, Eisenhofer G. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann NY Acad Sci. 2002; 970:29–40.

    Article  PubMed  CAS  Google Scholar 

  9. Mayo CH. Paroxysmal hypertension with tumor of retroperitoneal nerve: report of case. JAMA. 1927; 89:1047–50.

    Article  Google Scholar 

  10. Kvale WF, Manger WM, Priestley JT, Roth GM. Pheochromocytoma. Circulation. 1956; 14:622–30.

    Article  PubMed  CAS  Google Scholar 

  11. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology. 2002; 222:629–33.

    Article  PubMed  Google Scholar 

  12. Elsayes KM, Mukundan G, Narra VR, Lewis JS Jr, Shirkhoda A, Farooki A, et al. Adrenal masses: mr imaging features with pathologic correlation. Radiographics. 2004; 24 Suppl 1:S73–86.

    Article  PubMed  Google Scholar 

  13. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002; 287:1427–34.

    Article  PubMed  CAS  Google Scholar 

  14. Sawka AM, Jaeschke R, Singh RJ, Young WF, Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003; 88:553–8.

    Article  PubMed  CAS  Google Scholar 

  15. Hickman PE, Leong M, Chang J, Wilson SR, McWhinney B. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology. 2009; 41:173–7.

    Article  PubMed  CAS  Google Scholar 

  16. Christensen TT, Frystyk J, Poulsen PL. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma. Scand J Clin Lab Invest. 2011; 71:695–700.

    Article  PubMed  CAS  Google Scholar 

  17. Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. Am J Roentgenol. 2013; 200:370–8.

    Article  Google Scholar 

  18. Baez JC, Jagannathan JP, Krajewski K, O’Regan K, Zukotynski K, Kulke M, et al. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012; 12:153–62.

    PubMed  Google Scholar 

  19. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003; 88:2656–66.

    Article  PubMed  CAS  Google Scholar 

  20. Messerli FH, Frohlich ED. High blood pressure. A side effect of drugs, poisons, and food. Arch Intern Med. 1979; 139:682–7.

    Article  PubMed  CAS  Google Scholar 

  21. Lenz T, Ross A, Schumm-Draeger P, Schulte KL, Geiger H. Clonidine suppression test revisited. Blood Press. 1998; 7:153–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Dr. Carr and Dr. Spanheimer were supported by NIH T32 Grant CA148062-01.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James R. Howe MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carr, J.C., Spanheimer, P.M., Rajput, M. et al. Discriminating Pheochromocytomas from Other Adrenal Lesions: The Dilemma of Elevated Catecholamines. Ann Surg Oncol 20, 3855–3861 (2013). https://doi.org/10.1245/s10434-013-3142-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3142-z

Keywords

Navigation